Voluntary Licensing Practices in the Pharmaceutical Sector: An Acceptable Solution to Improving Access to Affordable Medicines?
Tahir Amin, Oxfam
I-MAK’s team has spent the last decade increasing transparency on patents, innovation, and access.
Voluntary Licensing Practices in the Pharmaceutical Sector: An Acceptable Solution to Improving Access to Affordable Medicines?
Tahir Amin, Oxfam
India’s Patent Act On Trial
In May 2006, Novartis challenged India’s standard for patentability of an invention as being unconstitutional and not in compliance with the WTO’s TRIPS Agreement. The outcome of the case is likely to have major implications for many developing countries.
Urgent Need for Second-Line HIV Treatment
Radhakrishnan and Abraham, Indian Medical Parliamentarians Forum
Data Exclusivity – The Impact of Article 39.3 in India: A Practical Perspective
Using examples of medicines that are already on the market, and some which do not yet have marketing approval in India, we attempt to demonstrate how the current proposal of a three-year data exclusivity period would impact access to these medicines.
A Critique of Patents (Amendment) Bill 2005
Gopakumar and Amin, Economic and Political Weekly
Implications of India’s New Patent Law
On 23 March, the Indian Parliament passed a new Patents Act, which brought the country into compliance with its WTO obligations. Heavily politicised amendment negotiations secured the continuation of pharmaceutical exports to least-developed countries, as well as the right to oppose patent applications on a number of grounds. However, some flexibilities under the TRIPS Agreement…
Partner with us now to build
a more just and equitable
medicine system for all.